Overview
SOFTCARE (2698)
Softcare Limited operates as a hygiene product corporation principally engaged in the development, manufacturing, and sales of baby and feminine hygiene product...
- Open
- 26.940
- High
- 27.420
- Low
- 26.720
- Prev. Close
- 26.920
- Volume
- 870.95K
- Turnover
- 23.62M
- Avg Price
- 27.120
- Bid/Ask Ratio
- 85.19%
- Amplitude
- 2.60%
- 52wk High
- 35.273
- Volume Ratio
- 0.27
- Turnover Ratio
- 0.14%
- 52wk Low
- 23.233
- HK Mkt Cap
- 16.79B
- Market CapHKD
- 16.79B
- P/ETTM
- 14.76
- P/EDynamic
- 14.12
- P/EStatic
- --
- EPSTTM
- 1.83
- EPSDynamic
- 1.92
- EPSStatic
- --
- BVPS
- 8.36
- P/B
- 3.23
- HK Shares
- 620.81M
- Dividend YieldTTM
- 4.89%
- DividendTTM
- 1.323
- Shares
- 620.81M
- Min lot size
- 200
- Currency
- HKD
SOFTCARE Analyst Rating
View moreForecast & Rating
Oct 27, 2026- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 8
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 10
Softcare rose 3.27% to HK$28.40 from HK$27.50, reversing an early dip to HK$27.58 and rallying to HK$28.96 in the afternoon, as falling oil prices eased input costs and share gains proceeded as expected, on HK$48.19 million turnover and a thin 0.27% turnover rate. That operating momentum contrasts with the price: Q2 2026 revenue rose 30.56% year on year to HK$1.305 billion, net profit 45.86% to HK$297.3 million at a 22.79% margin, EPS 0.4784 up 20.68% and ROE 22.90%, yet the stock is still 22.83% below its HK$36.80 52-week high, down 9.38% year to date and only just above the HK$28.43 MA60 and HK$25.94 MA20. CLSA keeps a HK$41 target, with consensus nearly 50% above spot, and the company has proposed a restricted stock unit plan. Though the interim report has yet to be fully digested and the shares remain capped near MA60 after a more than 20% retreat from the high.
- Nov, 6
After a 6%-plus gain the prior session on expectations that lower oil prices would ease input costs, Softcare reversed intraday: it tagged HK$29.20 at 09:52, slid to HK$27.56 at 15:29 and closed at HK$27.80, down 4.2% from the prior close of HK$29.02 on HK$47.2 million turnover. The pullback sits against strong fundamentals, with Q2 2026 revenue of HK$1.305 billion up 30.56% year on year, net profit of HK$297 million up 45.86%, net margin at 22.79% and EPS of HK$0.4784 up 20.68%, putting the shares on 15.17x PE. Price positioning remains mid-range: down 11.3% year to date, 24.46% below the 52-week high of HK$36.80 and 16.51% above the June low of HK$23.86, holding above the MA20 of HK$25.75 but below the MA60 of HK$28.66, while CLSA maintains its HK$41 target and Outperform rating. Though the CEO's earlier sale of 2.162 million shares at HK$28.7 keeps near-term supply in focus.
- Nov, 5
Softcare rose 5.83% to HK$29.02 as falling oil prices eased the cost side and market-share gains proceeded in line with expectations; the stock spiked to HK$29.80 at 10:49 in the morning session, slipped to HK$28.48 in the afternoon and settled near HK$29.02 on HK$117.6 million turnover. Fundamentals and price still diverge: Q2 2026 revenue grew 30.56% year on year to HK$1.305 billion and net profit 45.86% to HK$297.3 million, a 22.79% net margin with 22.9% ROE, yet the shares are down 7.4% year to date, 21.14% below the 52-week high of HK$36.80 and only just above the MA60 of HK$28.78 and MA20 of HK$25.66. CLSA keeps a HK$41 target price as an external valuation reference, while CEO Luo Jichao's earlier sale of 2.162 million shares at HK$28.7 remains a counterweight.
- Nov, 4
Softcare (2698.HK) staged a low-open, single-direction advance, closing at HK$27.42 for a 7.87% gain on the prior close of HK$25.42, as buyers concentrated in the afternoon after CLSA reiterated its HK$41 target; the session low of HK$25.42 printed at 09:35 BJ and the high of HK$27.54 at 15:56, with the close near the top of the range. Fundamentals contrast with the price position: Q2 2026 revenue of HK$1.305bn rose 30.56% yoy and net profit of HK$297.3m rose 45.86%, a 22.79% net margin at 14.97x PE and 3.28x PB on a HK$17.0bn market cap with a thin 0.40% turnover rate, yet the stock is still down 12.51% YTD, 25.49% below its 52-week high of HK$36.80 and under the MA60 of HK$28.88, holding only above the MA20 of HK$25.49. Though CEO Luo Jichao earlier sold 2.162 million shares at HK$28.7, supply near that level may still need absorbing.
- Nov, 3
Softcare opened at HK$25.06, spiked 7.1% to HK$26.84 in the first minutes of the morning session, then gave back the entire gain to HK$24.84 by 10:45 before recovering to HK$25.42, a 1.44% close, matching reports that the stock climbed 7% in Hong Kong trading and pointing to concentrated selling near HK$26.8. The pullback sits against strong interim numbers: Q2 revenue of HK$1.305bn rose 30.56% yoy, net profit of HK$297.3m rose 45.86%, net margin reached 22.79% and EPS of HK$0.4784 rose 20.68%, while CLSA kept a HK$41 target. Price positioning still lags that operating trend: at HK$25.42 the shares are below the 60-day MA of HK$29.01, down 18.89% YTD, 30.92% below the 52-week high of HK$36.8 and only 6.54% above the 52-week low of HK$23.86, oscillating around the 20-day MA of HK$25.41; though CEO Luo Jichao's earlier sale of 2.162m shares at HK$28.7 remains overhead supply.
News
Weekly Review · Weekly Recap | SOFTCARE +10.93%, consensus target nearly 50% above spot
Market Movers · Softcare climbs 6% in Hong Kong trading
Market Movers · Softcare climbs 7% in Hong Kong trading
Global Report · Seven Months Suspended: Hong Kong Small Caps Are Losing the Trust War
Global Report · For Ten Overlooked Hong Kong Names, the Pricing Anchor Has Moved Overseas
Global Report · Aluminium's four-year surge, and the Hong Kong small caps making their own news
